Introduction to
FFPE Samples with Whole Genome Sequencing Data
FFPE Whole Genome Sequencing Samples for Oncology Research
FFPE whole-genome sequencing samples provide preserved tumour tissue accompanied by genomic information extending beyond protein-coding regions. WGS can potentially identify single-nucleotide variants, insertions, deletions, structural variants, copy-number changes and alterations in non-coding regions. This broad genomic view can support oncology research involving tumour evolution, genomic instability, rare alteration discovery and resistance mechanisms. However, FFPE tissue presents technical challenges because formalin fixation can fragment DNA and introduce artefacts.
Researchers should therefore review DNA quality, sequencing depth, tumour purity, library preparation and bioinformatics filtering. Matched normal DNA is particularly valuable for distinguishing somatic variants from inherited changes. The corresponding FFPE tissue can be used for orthogonal validation, IHC, FISH, spatial analysis or repeat extraction when sufficient material remains. Pathologist review should confirm diagnosis and representative tumour content. High-quality FFPE samples with carefully generated WGS data can support advanced genomic research when accompanied by transparent methodology and quality-control documentation.
Buy FFPE Tumor Blocks With Whole Genome Sequencing Data
FFPE tumour blocks with whole-genome sequencing data can support research programmes that require a broad and relatively unbiased view of the cancer genome. Samples may be selected according to disease indication, histological subtype, tumour stage, metastatic status or specific genomic characteristics. The accompanying WGS package may include raw sequencing reads, aligned files, variant calls and an interpreted report. Researchers should verify whether the data were generated from the exact block being supplied and whether matched normal material was included.
Optimized for DNA Sequencing
NGS-Ready FFPE Tissue Blocks
Reliable RNA Profiling Samples
FFPE Whole Genome Sequencing for Genomic Biomarker Studies
FFPE whole-genome sequencing can help researchers explore genomic biomarkers that may not be fully captured by targeted panels or exome sequencing. WGS may reveal structural variants, copy-number patterns, complex rearrangements and alterations within coding and non-coding regions. Researchers can investigate whether these genomic features are associated with tumour subtype, prognosis, treatment response or resistance. Candidate findings can then be evaluated in the corresponding FFPE tissue using PCR, FISH, IHC or other orthogonal methods.
Clinically Annotated Tissue Samples
FFPE blocks supplied with relevant clinical details for reliable genomic research.
Comprehensive Pathology Data Included
Each sample includes diagnosis, grade, stage, tumor content, and pathology information.
Optimized for Genomic Analysis
Samples are suitable for DNA, RNA, NGS, mutation analysis, and molecular profiling.
Reliable Samples for NGS
Quality-controlled FFPE blocks support accurate sequencing and reproducible genomic results.
Source WGS-Profiled FFPE Tumor Samples for Research
WGS-profiled FFPE tumour samples can be sourced through a customised process based on cancer type, sample characteristics, genomic findings and data requirements. Researchers should specify the number of cases, tumour subtype, stage, tissue format, minimum tumour content and acceptable necrosis. The request should also identify which genomic files are required, such as FASTQ, BAM, CRAM, VCF or structural-variant outputs. Information about the sequencing platform, library preparation, mean coverage, matched normal sample and bioinformatics pipeline should be reviewed before selection.
Pathological quality control can confirm diagnosis, tissue integrity and the amount of representative tumour remaining in each block. Clinical annotations may be included where ethically permitted and available. Researchers should establish secure mechanisms for transferring large WGS datasets and protecting genomic privacy. A clear acceptance and replacement policy can address samples that fail pathology or nucleic-acid quality criteria. Structured sourcing helps create traceable, research-ready WGS cohorts for pharmaceutical, biotechnology and academic programmes.
Clinically Annotated FFPE Samples With WGS Data
Clinically annotated FFPE samples with WGS data allow researchers to connect broad genomic findings with pathological features, treatment history and patient outcomes. The clinical dataset may include diagnosis, stage, grade, therapies administered, response, progression and survival follow-up. Such cohorts can support exploratory studies of genomic predictors, resistance mechanisms and disease evolution. Researchers must examine the completeness and consistency of clinical annotations, especially when samples originate from multiple institutions. WGS data should be accompanied by information about sequencing depth, tumour purity, matched normal analysis and the bioinformatics pipeline used to identify variants. Tissue-level quality control should verify diagnosis, tumour content, necrosis and remaining material. Since whole-genome information presents particular privacy considerations, specimens and data must be de-identified and handled under appropriate consent, ethics and data-security frameworks. When clinical, genomic and pathological elements are properly harmonised, these samples can support advanced translational research and multimodal computational modelling.
Order FFPE Whole Genome Sequencing Samples and Datasets
FFPE samples and matched whole-genome sequencing datasets can be ordered as an integrated research package. The specification should identify the tumour indication, number of cases, sample format, sequencing deliverables and required clinical annotations. Physical materials may include FFPE blocks, unstained slides, tissue curls or extracted DNA. Genomic deliverables may include raw sequence files, aligned reads, variant files, copy-number outputs, structural-variant results and summarised reports. Researchers should confirm that the physical tissue and sequencing dataset originate from the same specimen or clearly documented matched material. Important quality metrics include tumour purity, DNA yield, sequencing coverage and the proportion of usable reads. Matched normal data should be requested when accurate somatic variant detection is essential. Secure genomic-data transfer, informed consent, ethical approval and data-use agreements should be established before delivery. An integrated ordering model gives researchers access to broad genomic information while preserving physical tissue for confirmation, additional assays and future studies.
General Questions
Frequent Asked Questions!!
FFPE blocks for genomics are formalin-fixed, paraffin-embedded tissue samples used for DNA, RNA, and biomarker analysis. They are widely used in cancer genomics, molecular pathology, translational research, and retrospective studies.
FFPE tissue blocks are valuable because they preserve tissue architecture and molecular material for long-term storage. Researchers can use them for sequencing, mutation analysis, biomarker discovery, and validation studies.
Yes. DNA can be extracted from FFPE blocks using validated extraction kits and optimized laboratory protocols. DNA quality depends on fixation time, block age, tissue type, tumor content, and storage conditions.
Yes. RNA can be extracted from FFPE tissue, although it is often fragmented because of formalin fixation. Specialized FFPE RNA extraction methods can provide material suitable for targeted RNA sequencing, gene expression studies, and fusion analysis.
Yes. High-quality FFPE blocks are commonly used for next-generation sequencing, including targeted sequencing panels, whole-exome sequencing, RNA sequencing, and selected whole-genome applications.
Tumor content requirements depend on the study design and testing method. Many molecular and NGS studies require at least 20% tumor content, while some projects may require 30%, 50%, or higher tumor percentage. Pathologist review can be performed to confirm tumor content before shipment
FFPE blocks can support mutation testing, copy number analysis, gene fusion detection, microsatellite instability testing, tumor mutational burden analysis, methylation studies, and targeted DNA or RNA sequencing.
Yes. FFPE cancer tissue blocks are extensively used to study genomic alterations in lung, breast, colorectal, prostate, ovarian, pancreatic, liver, kidney, and other tumor types.
Researchers can purchase FFPE blocks from qualified biospecimen suppliers, biobanks, pathology laboratories, hospitals, and research networks that provide ethically sourced and clinically annotated human tissue samples.
Researchers should confirm diagnosis, tissue type, tumor percentage, necrosis percentage, fixation details, block age, specimen size, available clinical data, pathology review, consent status, and intended research-use permissions.
Yes. Clinically annotated FFPE blocks may include donor age, sex, diagnosis, grade, stage, TNM classification, treatment history, pathology report, mutation status, and clinical outcome data.